Simris Group AB Signs Non-Binding Concept Sheet for Potential Antibody-Drug Conjugate Collaboration
Simris Group AB (publ), through its wholly owned subsidiary Simris Biologics GmbH, has signed a non-binding concept sheet with a EU based biopharmaceutical company specializing in the development of novel antibody-drug conjugates (ADCs). The concept sheet outlines the intention of both parties to explore a potential Research, Development Option and License Agreement focused on Simris’ proprietary cytotoxin payloads derived from cyanobacteria.
The aim of the concept sheet is to provide a framework for continued discussions and negotiations toward a definitive agreement.
“This marks an exciting step in Simris Biologics’ strategy to expand the potential applications of our toxin payloads by partnering with established innovators in targeted cancer therapeutics,” said Dr. Alexis Roberts-McIntosh, CEO of Simris Group AB. “The discussions outlined in the concept sheet are focused on evaluating the integration of Simris’ cyanobacteria-derived payloads into next-generation ADC constructs.”
The concept sheet is non-binding and intended solely as a basis for further discussion. It does not constitute an offer or create any binding legal obligations between the parties. Any future collaboration remains subject to the successful negotiation and execution of a definitive agreement.
Further updates will be provided as material developments occur.